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Abstract
A major challenge in breast cancer therapy is the lack of an effective therapeutic option for a particularly aggressive subtype
of breast cancer, triple-negative breast cancer. Here we provide the first preclinical evidence that a second-generation
selenium compound, methylseleninic acid, significantly enhances the anticancer efficacy of paclitaxel in triple-negative
breast cancer. Through combination-index value calculation, we demonstrated that methylseleninic acid synergistically
enhanced the growth inhibitory effect of paclitaxel in triple-negative breast cancer cells. The synergism was attributable to
more pronounced induction of caspase-mediated apoptosis, arrest of cell cycle progression at the G2/M checkpoint, and
inhibition of cell proliferation. Treatment of SCID mice bearing MDA-MB-231 triple-negative breast cancer xenografts for
four weeks with methylseleninic acid (4.5 mg/kg/day, orally) and paclitaxel (10 mg/kg/week, through intraperitoneal
injection) resulted in a more pronounced inhibition of tumor growth compared with either agent alone. The attenuated
tumor growth correlated with a decrease in tumor cell proliferation and an induction of apoptosis. The in vivo study also
indicated the safety of using methylseleninic acid in the combination regime. Our findings thus provide strong justification
for the further development of methylseleninic acid and paclitaxel combination therapy for the treatment of triple-negative
breast cancer.
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Introduction
Triple-negative breast cancer (TNBC) refers to a subtype of
breast cancer that is negative for expression of estrogen receptor
and progesterone receptor, and lacks HER2 overexpression. The
majority of TNBCs bear the gene expression profile of basal-like
phenotype [1]. This subtype accounts for ,10–15% of all types of
breast cancer. TNBC is particularly aggressive, associated with
rapid relapse following therapy, increased prevalence of distant
metastases, and shorter survival comparing with other breast
cancer subtypes [2]. It is more prevalent in Hispanic and African
American women than in other ethnic groups, with the majority of
the cases occurring in premenopausal women [3,4].
Due to the ‘‘triple-negative’’ nature, patients with TNBC are
not candidates for endocrine therapy or targeted therapy against
HER2. TNBC patients are usually managed with standard
treatments, and chemotherapy is the primary, if not the only,
choice of systemic therapy. Taxanes, such as paclitaxel, alone or in
combination with anthracycline reagents and/or alkylation
reagents are the first-line chemotherapeutic drugs being used for
TNBC [2,5]. Although patients generally have a favorable initial
response to taxane regimens, rapid development of resistance to
taxanes is prevalent [5]. Therefore, developing agents that could
effectively enhance the efficacy of taxanes and overcome resistance
is urgently needed for the management of TNBC.
Selenium is an effective anticancer agent with a low toxicity
profile [2]. The anticancer efficacy depends on the form and
dosage of selenium administered [6–11]. Methylseleninic acid
(MSA) is a potent second-generation selenium compound. It has
very different biological and pharmacological activity than
selenomethionine, the form of selenium used in the Selenium
and Vitamin E Chemoprevention Trial [7,9–13]. MSA has been
shown to enhance the efficacy of chemotherapeutic drugs in
cultured estrogen-receptor-positive breast cancer cells as well as
cultured prostate cancer cells and prostate tumor xenografts [14–
17]. However, the effectiveness of MSA alone or in a combination
regime for treating TNBC has never been evaluated. In this
report, we describe a series of experiments that were designed to
determine the potential of using MSA to improve the therapeutic
outcome of paclitaxel for the treatment of TNBC.
Materials and Methods
TNBC Cell Lines and Reagents
MDA-MB-231, MDA-MB-157, and BT-549 cell lines were
obtained from American Type Culture Collection. MDA-MB-231
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BT-549 cells in RPMI 1640 medium. Both media were
supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 units per ml penicillin, and 100 mg/ml streptomycin.
Paclitaxel and MSA were purchased from Sigma.
Cell viability, Apoptosis, and Cell Proliferation Detection
Cell viability was determined by using either the Sulforhoda-
mine B (SRB) assay as described [18] or direct cell counting with
trypan blue staining. Cell proliferation was measured by using the
BrdU Cell Proliferation ELISA kit (Roche), and apoptosis of
cultured cells detected by using the Cell Death Detection
ELISA
PLUS Kit (Roche) as described [19,20]. The apoptotic cells
on tumor sections were detected by the TUNEL assay using the In
Situ Cell Death Detection Kit-TMR red (Roche) per manufactur-
er’s protocol. The TUNEL slides were counterstained with DAPI
for nuclear staining. The images were taken by using a Nikon
Eclipse 80i fluorescence microscope, and quantitated with the use
of the Image J software.
Western blot analysis
The procedure was described previously [21]. Immune-reactive
bands were quantitated by densitometry using the Licor Odyssey
software and normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). The antibodies for the active forms of caspase-3
(Catalog Number 9664) and caspase-7 (Catalog Number 9491),
and cleaved PARP (Catalog Number 5625) were obtained from
Cell Signaling. The GAPDH antibody was from Millipore
(Catalog Number Mab374).
Cell Cycle Analysis
Cells were detached from culture dishes by using 15 mM
EDTA-Na2, and then fixed in 70% ethanol. The cell pellet was
washed with PBS twice and suspended in propidium iodide
staining solution (0.1% (v/v) Triton X-100, 0.2 mg/ml DNase-free
RNase A, and 20 mg/ml propidium iodide). After incubation at
room temperature for 30 min, DNA content was analyzed by
using the BD LSRII flow cytometer. The Modfit LT
TM software
was used to analyze the data.
Caspase-3/7 Activity Assay
Caspase-3/7 activity was measured by using the Caspase 3/7-
Glo assay kit (Promega) according to manufacturer’s manual. The
reading was measured by using the Fluostar Optima fluorescent
plate reader.
MDA-MB-231 Tumor Xenograft Model
Female SCID hairless out-bred mice were obtained from
Charles River at 8 weeks of age. The mice were kept in vivarium
for two weeks to adapt before any procedure. One million MDA-
MB-231 cells in PBS were inoculated into both sides of the
mammary fat pad with Matrigel. When tumors were palpable,
,4–6 weeks after the inoculation, the mice were randomly
assigned to four groups. Control mice were given weekly
intraperitoneal saline solution. The MSA group was treated with
3 mg selenium in the form of MSA per kg body weight daily by an
oral route [22]. Paclitaxel, 10 mg/kg, was given by intraperitoneal
injection weekly. The combination group was treated with daily
oral MSA and weekly intraperitoneal paclitaxel. Body weights and
tumor dimensions were monitored weekly. Tumor volume was
calculated as 0.524 x width
2 x length. At the end of the experiment,
mice were anesthetized, and tumors removed, weighed, and fixed
in 10% formalin for paraffin embedding and histological analyses.
All animal procedures were approved by the Tulane University
Institutional Animal Care and Use Committee.
Immunohistochemical (IHC) Analysis
Paraffin-embedded blocks were sectioned, deparaffinized,
rehydrated, and quenched by immersing in 1% H2O2. The slides
were boiled in 10 mM citrate buffer (pH 6.0) for 20 min for
antigen retrieval, and pre-incubated with 5% blocking serum to
prevent non-specific binding. Ki-67 antibody incubation was
applied at room temperature for 1 hr. Ki-67 reaction was
visualized by using the VECTASTAIN ABC system (Vector),
with diaminobenzidine as the chromogen. Sections were counter-
stained with hematoxylin. As the negative control, the primary
antibody was replaced with a non-immune IgG at the same
concentration, and no reactivity was detected. The IHC images
were analyzed by using the ImmunoRatio online analysis
tools [23].
Statistical Analysis
Mean activities were calculated from at least three independent
experiments performed in triplicate. The Student’s two-tailed t test
assuming unequal variance was used to determine significant
differences between two groups.
Results
MSA synergistically enhances the growth-inhibitory
efficacy of paclitaxel in MDA-MB-231 cells
We chose the most commonly-used and well-studied TNBC cell
line, MDA-MB-231 [24–28], as the primary model for investigat-
ing the combinatory effect of MSA and paclitaxel. MDA-MB-231
was derived from pleural effusion of a breast cancer from a
Caucasian patient [29]. Cells were treated with pharmacologically
achievable concentrations of MSA, paclitaxel, or the two drugs in
combination for 72 hr. Cell viability was first determined by the
SRB assay. The cell viability in all combination groups was lower
than that in the respective single-agent treatment groups (Table 1).
To determine whether these combinatory effects were synergistic,
the data were analyzed with the Calcusyn software (Biosoft), which
calculates combination index (CI) values using the median-effect
principle [30] to delineate the interaction between two drugs. A CI
value of ,1, 1, or .1 denotes synergism, additivity, or
antagonism, respectively. All the combinations, except 2.5 mM
MSA and 10 nM paclitaxel, produced a CI value of less than 1,
suggesting a synergy between MSA and paclitaxel in inhibition of
cell growth (Table 2). We also assessed cell viability by direct cell
counting with trypan blue staining, and the data (Fig. 1) are
congruent with the SRB results.
Inhibition of cell proliferation by MSA and paclitaxel
To elucidate the mechanism underlying the synergism between
MSA and paclitaxel, we evaluated cell proliferation in response to
the treatments in MDA-MB-231 cells. Cells were treated for 16 hr
at the lowest dose combination, viz., 3.2 mM MSA and 10 nM
paclitaxel, which produced a synergistic effect on growth
inhibition. The cell proliferation data (Fig. 2A) were normalized
by the SRB reading, and expressed as percentage of the vehicle
control. The combination treatment induced slight, but significant,
inhibition of proliferation comparing to the control group. Similar
pattern of inhibition was observed at the 24 and 36 hr time points
(data not shown). The data suggest that inhibition of proliferation
contributes to the synergistic effect between MSA and paclitaxel,
but may not be the major contributing factor.
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We next assessed the effect of the combination treatment on cell
cycle distribution. The experiment was performed at the 24-hr
time point in MDA-MB-231 cells. As depicted in Table 3,
paclitaxel decreased the proportion of cells in G0/G1 and arrested
cells in G2/M phase. At the 3.2 mM concentration, MSA alone
didn’t affect cell cycle distribution. However, it enhanced the
paclitaxel effect by further decreasing the fraction of cells in G0/
G1 phase and increasing G2/M arrest.
MSA enhances paclitaxel-induced apoptosis
G2/M arrest induced by paclitaxel in cancer cells generally
leads to extensive apoptosis [31]. We therefore evaluated apoptosis
in MDA-MB-231 cells. As shown in Fig. 2B, an increase in
apoptosis was observed after treatment of cells with either MSA or
paclitaxel, and the increase was more pronounced as a result of the
combination treatment. Caspase-PARP activation is the major
pathway involved in apoptosis. We measured caspase-3 and -7
activation and PARP cleavage in MDA-MB-231 cells by Western
blotting. Consistent with the apoptosis data, the combination
treatment caused an enhanced activation of caspase-3 and -7 and
PARP cleavage comparing to either MSA or paclitaxel alone
(Fig. 2C). We also performed caspase-3/7 activity assay, and the
activity data correlated well with the Western result (Fig. 2D). In
addition, pre-treatment of cells with a pan-caspase inhibitor (Z-
VAD-FMK) almost completely blocked apoptosis induction
(Fig. 3A) and inhibition of cell viability (Fig. 3B) by paclitaxel,
alone or in combination with MSA, demonstrating the caspase-
PARP pathway as the major pathway involved.
MSA enhances paclitaxel-induced inhibition of
proliferation and increase of apoptosis in other TNBC cell
models
To further demonstrate the universality of the combinatory
effects, we determined cell proliferation and apoptosis in two other
TNBC cell models, MDA-MB-157 and BT-549. MDA-MB-157
was derived from pleural effusion of a breast cancer from an
African-American patient, and BT-549 from a primary breast
cancer from a Caucasian patient [29]. In both models, the
combination treatments led to a more robust induction of
apoptosis and inhibition of proliferation than treatment with
MSA or paclitaxel alone (Fig. 4).
MSA enhances paclitaxel efficacy in vivo
To evaluate the in vivo efficacy of MSA and paclitaxel, female
SCID-hairless mice implanted with MDA-MB-231 cells were
divided into four groups receiving saline solution as control, 3 mg
selenium in the form of MSA per kg body weight daily, 10 mg/kg
paclitaxel weekly, or the two drugs in combination. To be more
consistent with the patient treatment schedule, all treatments were
stopped after 4 doses of paclitaxel, and mice were maintained for
an additional 4 weeks. As shown in Fig. 5A, MSA alone had no
effect on tumor growth. In the paclitaxel group, tumor growth was
suppressed until two weeks after termination of treatment, and
tumor re-growth was observed on Day 42. The re-growth was
greatly inhibited by the combination treatment. At the conclusion
of the study, the average tumor weight in the paclitaxel group was
significantly lower than that in the control group, and the
combination treatment caused a more pronounced reduction of
tumor weight (Fig. 5B). The combination treatment did not appear
to cause more toxicity than paclitaxel alone since mice in the two
groups had similar body weights (Fig. 5C). We then measured
apoptosis induction by using the fluorescent TUNEL assay and
proliferation index by Ki-67 IHC in the xenograft tumors. As
shown in Fig. 6, the combination treatment led to a significant
induction of apoptosis and inhibition of cell proliferation in the
tumors.
Discussion
In the present study, we evaluated the efficacy of MSA in
combination with paclitaxel for the treatment of TNBC. Our data
showed that MSA could significantly enhance the in vitro and in vivo
antitumor efficacy of paclitaxel in TNBC cells. Through CI value
calculation for MSA and paclitaxel, each at three different
concentrations, we demonstrated that the combinatory effect on
cell growth, except that of the lowest dose combination, was
Figure 1. MSA enhances the efficacy of paclitaxel in inhibiting
the growth of MDA-MB-231 cells. Cells were treated with 3.2 or
4 mM MSA, 10 nM paclitaxel, or the combinations for 72 hr. Live cells
were counted with trypan blue staining.
doi:10.1371/journal.pone.0031539.g001
Table 1. Effect of MSA and/or paclitaxel on cell viability*.
Paclitaxel (nM) MSA (mM)
02 . 53 . 24
0 100 90.0613.2 80.3613.2 60.7610.5
10 47.865.7 44.760.8 35.361.3 29.761.7
20 42.662.8 35.862.3 30.361.7 26.163.8
40 38.762.0 37.763.3 28.160.4 25.062.6
*Results are expressed as % of vehicle control (mean 6 SEM).
doi:10.1371/journal.pone.0031539.t001
Table 2. Combination Index values for MSA and paclitaxel.
Paclitaxel (nM) MSA (mM)
2.5 3.2 4
10 1.163 0.752 0.761
20 0.796 0.696 0.73
40 0.812 0.726 0.758
doi:10.1371/journal.pone.0031539.t002
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induction of caspase-mediated apoptosis, arrest of cell cycle
progression at the G2/M checkpoint, and inhibition of cell
proliferation. Our in vivo study also showed the safety of using
MSA in the combination regime. The current study is the first to
show the in vivo effectiveness of MSA in enhancing chemothera-
peutic efficacy in breast cancer. The focus on TNBC could be of
more clinical importance considering the limited availability of
effective treatment options for this deadly disease. An interesting
observation that needs to be pointed out is that when MSA was
combined with paclitaxel at their respective lowest tested
concentration, the combination produced antagonistic effect
(CI=1.163). The clinical relevance of this observation requires
further in vivo testing. If proven to be true, the information could be
helpful in selecting the effective doses of the two drugs for future
clinical trials.
MSA, at the dose used in our in vivo study, has been shown to
inhibit the growth of prostate tumor xenografts [14]. However, no
growth inhibition was observed in our study with the MDA-MB-
231 xenograft model. This discrepancy could be due to the
difference in the model system. It could also result from the
difference in the treatment protocols. In the prostate tumor
studies, MSA treatment was initiated right after cell inoculation
and continued until the end of the experiments. However, in our
study, MSA supplementation was not started until the tumors
became palpable. The mice were administered MSA for only 4
weeks, and were maintained drug-free thereafter. Although there
was a slight trend of growth inhibition during MSA treatment, this
inhibition was not significant because the tumors were rather
small. Whether MSA treatment, in a long term or at a higher dose,
could inhibit the growth of TNBC tumors awaits to be
determined. In our study, paclitaxel alone dramatically inhibited
the growth of the xenograft tumors. However, this was not
accompanied by a significant change in apoptosis or proliferation.
This could again arise from our treatment and recovery
experimental protocol.
Previously, we reported that MSA can induce FADD expression
in MCF-7 breast cancer cells [16]. This boost of FADD expression
leads to recruitment of caspase-8, resulting in a robust apoptosis
induction when combined with chemotherapeutic reagents.
FADD has been shown to play an important role in G2/M arrest
Figure 2. MSA enhances the efficacy of paclitaxel in inhibiting cell proliferation and inducing apoptosis, caspase activation, and
PARP cleavage in MDA-MB-231 cells. Cells were treated with 3.2 mM MSA, 10 nM paclitaxel, or the combination for 16 hr. Cells were then
analyzed for proliferation (A), apoptosis (B), the levels of active form of caspase-3 and -7, and cleaved PARP by Western blotting (C), or Caspase-3/7
activity (D). The BrdU, apoptosis, and caspase-3/7 activity readings were normalized by the SRB reading in cells set up in parallel. Error bars, SEM.
*, statistically significant (P,0.05) from the control group. **, statistically significant (P,0.05) from both single–agent-treated samples and the control
sample. Pac, paclitaxel.
doi:10.1371/journal.pone.0031539.g002
Table 3. Effect of MSA and/or paclitaxel on cell cycle
distribution
#.
Treatment Group G0/G1 S G2/M
Control 58.364.5 27.762.8 14.061.7
MSA 59.164.9 24.264.1 16.760.9
paclitaxel 33.565.6* 29.960.4 36.765.2*
combination 26.466.5** 27.364.4 46.3610.9**
#Results are expressed as mean % of cells in a specific phase of cell cycle 6
SEM.
*Significantly different compared to the control group (P,0.05).
**Significantly different compared to both single-agent-treated and control
groups (P,0.05).
doi:10.1371/journal.pone.0031539.t003
MSA Enhances Paclitaxel Efficacy
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31539and cell growth suppression induced by paclitaxel in breast cancer
cells [32,33]. These findings suggest that increasing FADD
expression by MSA may lower the threshold for G2/M arrest
induced by paclitaxel treatment, consequently leading to increased
sensitivity to paclitaxel. FADD activation also may result in
activation of caspase-3 in TNBC cells, which in turn leads to
activation of caspase-8 or -9 and apoptosis. The FADD-caspase-3
axis should be tested in future studies to further elucidate the
mechanism underlying the combinatory effect of MSA and
paclitaxel.
When compared with other types of breast cancer, TNBC has
an increased rate of pathologic complete response to chemother-
apy. However, TNBC is associated with more prevalent and
earlier-onset recurrence and shorter overall survival [2]. Failure of
Figure 3. Inhibiting caspase activity attenuates apoptosis induction and growth suppression by MSA and paclitaxel in MDA-MB-
231 cells. Cells were pre-treated with 50 mM pan-caspase inhibitor Z-VAD-FMK prior to treatment with 3.2 mM MSA, 10 nM paclitaxel, or the
combination. Apoptosis was determined at the 16-hr time point by Cell Death ELISA (A), and cell viability at 72 hr by SRB (B). Error bars, SEM.
*, statistically significant (P,0.05) from the corresponding control sample not treated with the caspase inhibitor. Pac, paclitaxel.
doi:10.1371/journal.pone.0031539.g003
Figure 4. MSA enhances the effect of paclitaxel in inhibiting cell proliferation and inducing apoptosis in MDA-MB-157 and BT-549
cells. Cells were treated with MSA, paclitaxel, or the combination for 48 hr, and then subjected to analysis for proliferation (A, B) or apoptosis (C, D).
The BrdU and apoptosis readings were normalized by the SRB reading in cells set up in parallel. Error bars, SEM. *, statistically significant (P,0.05)
from the control group. **, statistically significant (P,0.05) from both single-agent-treated sample and the control sample. Pac, paclitaxel.
doi:10.1371/journal.pone.0031539.g004
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of G2/M transition genes, polyploidy induction, or multi-
nucleation, has been shown to be the major mechanism
underlying acquired resistance to paclitaxel [34]. Our finding that
MSA could enhance paclitaxel-mediated G2/M arrest suggests the
potential of using MSA to overcome paclitaxel resistance. In fact,
we generated a paclitaxel-resistant MDA-MB-231 subline by long-
term treatment of MDA-MB-231 cells with low doses of paclitaxel.
We found that MSA could reverse the resistance of the cells to
paclitaxel (data not shown). This further demonstrates the benefit
of using MSA in combination with paclitaxel for the management
of TNBC.
According to the 2010 cancer statistics report from the
American Cancer Society [35], cancer deaths have declined for
both Caucasian and African Americans living in the United States.
However, African Americans continue to suffer the greatest
Figure 5. MSA enhances paclitaxel efficacy in vivo. (A) Tumor growth curve. Data are presented as tumor volumes in each group (n=6
tumors/group). (B) Average tumor weight in each group at the end of the experiment. (C) Average body weight of the mice in each group. Error
bars, SEM. *, statistically significant (P,0.05) from the control group. **, statistically significant (P,0.05) from both single-agent-treated sample and
the control sample. Pac, paclitaxel.
doi:10.1371/journal.pone.0031539.g005
Figure 6. Induction of apoptosis and inhibition of tumor proliferation by paclitaxel and MSA in MDA-MB-231 xenograft. (A) TUNEL
staining. Data are presented as mean number of TUNEL-positive cells in each image. (B) Ki-67 IHC. Data are presented as mean % of Ki-67-positive
cells. Error bars, SEM. *, statistically significant (P,0.05) from both single-agent-treated sample and the control sample. Pac, paclitaxel. Right panels:
Representative images from each group.
doi:10.1371/journal.pone.0031539.g006
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Caucasian women have the highest incidence rate for breast
cancer, although African American women are most likely to die
from the disease [35]. The disparity could be attributable to many
factors, such as genetic, socioeconomic, diet, and culture
differences [3]. TNBC is the only subtype of breast cancer that
displays racial disparity [2]. Selenium concentration has been
shown to be inversely associated with the incidence of a number of
cancers, including breast cancer [36,37]. Serum selenium
concentration in African Americans were found to be significantly
lower than that in Caucasians [38]. It is therefore possible that the
clinical benefit of MSA could be more evident in African
Americans with TNBC.
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